The Flu Never Came, the Cliff Landed Soft: Upgrading Into an 8.8% De-Rating

Results vs. Consensus

Q1 2026 Scorecard

Consensus providers straddle this print. One provider marks a fractional miss on both revenue and EPS; a broader sell-side panel had EPS at $7.14 and revenue at $19.10B, which would make it a fractional beat. The spread between provider marks is roughly $0.03, well inside the noise band, so the honest characterisation of both headline lines is "in line."

The scorecard's shape is the story: the two lines the market watches were in line, and every line beneath them was soft. Management did not hide from it.

"our results were a bit short in terms of adjusted EBITDA to our internal expectations. Besides our internal expectations is being pretty consistent with the midpoint of our guidance in terms of growth, pretty consistent actually with consensus coming into the call." — Mike Marks, CFO

Year-Over-Year Comparison

Quarter-Over-Quarter Comparison

Q1 is seasonally weaker than Q4 for HCA, so the sequential declines are partly calendar rather than deterioration. The comparison is shown for completeness; the year-over-year table is the analytically meaningful one.

Revenue assessment. Same-facility equivalent admissions of 1.3% is below the 2% to 3% assumption underpinning full-year guidance, and management did not pretend otherwise, characterising it as "generally in line" but "at the lower end of the range." The quantification is what makes it credible: 70bps of the admissions shortfall and 140bps of the ER shortfall from the mild respiratory season, plus 30bps and 50bps respectively from the storm. Add those back and same-facility admissions growth of 0.9% becomes roughly 1.9%, which is inside the range. Reported figures also carry a portfolio drag, with hospitals at 189 against 192 a year ago and freestanding surgery centers at 119 against 125.

Margin assessment. The cost story has a wrinkle worth naming. Management said the respiratory season started strong in January and then ended abruptly, which combined with the storm to delay the ability to flex down seasonal staffing. That is a real and honest explanation for why a volume shortfall converted into a margin shortfall rather than being absorbed: HCA had staffed for a normal flu season that evaporated mid-quarter. Salaries and benefits still improved 30bps year over year despite that, which is a better outcome than the narrative implies.

EPS assessment. This is the quarter where the structural point we raised in January becomes concrete. HCA guided 2026 to flat net income with all per-share growth from buyback, and Q1 delivered exactly that, with the buyback doing even more work than guided because the tax rate helped. The company retired 3.157 million shares for $1.571B and has $9.179B of authorization remaining. The mechanism is functioning as designed. It is simply not the same thing as the business growing.

The Two Offsetting Shocks

The cleanest way to read Q1 2026 is as a quarter in which two large, unforecast items of similar magnitude ran in opposite directions and roughly cancelled. Both were disclosed with unusual precision.

The exchange line belongs in a different column from the other two. It was fully anticipated, is inside guidance, and is the item the entire 2026 debate has been about. It behaved.

Volume, Pricing and Payer Mix

Reported vs. Same-Facility Operating Statistics

Assessment: Inpatient revenue per admission of $20,327 on a same-facility basis, up 5.0%, is the standout and it is a direct consequence of the missing respiratory volume. Respiratory admissions are typically shorter-stay and lower-acuity, so losing 42% of them mechanically raises the acuity and revenue intensity of what remains. That also explains patient days falling 2.2% while admissions rose 0.7%, and length of stay improving to 4.782 days from 4.922. Part of the length-of-stay gain HCA has been claiming as an operational win is, this quarter, mix. Occupancy at 75.5% is the highest we have seen in this coverage, so capacity headroom is narrower than it was in Q3 2025.

Payer Mix (same-facility equivalent admissions, YoY)

Management said the respiratory and storm effects were "consistent across all payer categories," so the deceleration in commercial ex-exchanges, Medicare and Medicaid is partly the same weather-and-virology story rather than three separate problems. The exchange and uninsured lines are the structural ones.

Assessment: Uninsured equivalent admissions up 16% with only a little more than half attributable to exchange migration means something else is driving the rest, and management named it: a slowdown in Medicaid conversions because patients are less willing to complete Medicaid applications, which management suspects relates to immigration concerns. That is a genuinely new risk channel, it is not inside the $600M to $900M exchange estimate, and it converts patients who would previously have been Medicaid-reimbursed into uncompensated care. It is also the reason Medicaid volumes decelerated to 0.3%. We are adding this to the watch list as a distinct issue from the exchange transition.

The Exchange Transition: First Real Data

Two quarters ago the exchange exposure was undisclosed. One quarter ago it was a model. This quarter it is an observation, and the observation landed at the favorable end of the model.

Management also disclosed the accounting mechanics behind the 15% figure, which matter because they determine whether the number is conservative or optimistic. Exchange enrollees receiving premium assistance have a three-month grace period: the payer must cover care in month one, but for months two and three the payer is not obligated unless the premium is paid. HCA has no reliable, standardized visibility at the time of service as to whether a premium has been paid.

"our work, as we studied the quarter, was to first look at every patient that came in with exchange coverage and try our best to understand whether or not they attrited in -- they had an attrition during the quarter, at which point we recognize that revenue impact during the quarter, or to make an estimate of those that we believe will lose and come out of the grace period with attrition, where we will not get paid for that... when we articulate that 15% drop in equivalent admissions, it contains both of those components" — Mike Marks, CFO

Assessment: The 15% decline already includes an estimate for patients still inside their grace period who are expected to attrit. That makes the figure forward-leaning rather than a lagging count of confirmed losses, which is the conservative construction and is the reason we weight it heavily. The residual risk is that the grace-period estimate proves too small, and management flagged that the second quarter is when those patients resolve. That is a real caveat, and it is bounded by the fact that the full-year range was maintained on the basis of this analysis.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Direct about a disappointing quarter and unusually willing to quantify the reasons, including conceding a shortfall against both internal plan and consensus rather than reframing it. The confidence was concentrated where the evidence supports it, in the February and March recovery and in the exchange data tracking to model, and the hedging was concentrated where it belongs, in the grace-period estimates and in a North Carolina workforce problem management admitted is running behind plan. The decision not to raise guidance despite a $200M supplemental improvement was presented as prudence and was not fully explained.

1. The Respiratory Season That Did Not Happen

The dominant operating fact of the quarter, and it is a genuine outlier rather than a soft excuse. Respiratory-related admissions fell 42% and respiratory-related emergency room visits 32% against the prior-year quarter.

"From a volume perspective, we did not experience the typical lift related to seasonal respiratory conditions. Compared to the first quarter of last year, our respiratory-related admissions were down 42%, and our respiratory-related emergency room visits were down 32%." — Samuel Hazen, CEO

The cost consequence was worse than the revenue consequence, for a specific reason management explained rather than glossed.

"As we were coming into January, our respiratory season was actually strong at the beginning of the year. However, later in January, it became apparent that the respiratory season was actually ending abruptly. And we were then hit with a significant January winter storm across several of our states. Both the quick ramp down of the respiratory volume as well as the winter storm delayed our ability to flex down our seasonal cost in the quarter." — Mike Marks, CFO

Assessment: A 42% decline in a seasonal volume category is not a demand signal about HCA's business; it is epidemiology. The operationally meaningful detail is the staffing mismatch: HCA entered January staffed for a strong season, the season vanished mid-month, and the storm arrived simultaneously. That converted a revenue miss into a margin miss. It is also entirely self-correcting, and management said cost trends were back on plan by March. We treat the $180M as non-recurring.

2. Georgia, Texas Atlas, and a $200M Guidance Improvement Nobody Banked

Medicaid supplemental payments delivered approximately $200M of net benefit in the quarter against an $80M internal expectation, a $120M favorable variance driven by the grandfathered approval of Georgia and the reinstatement of the Texas Atlas program that was paused when we wrote our last note.

"We are adjusting our full year range to reflect the decline in supplemental payment program net benefit between $50 million to $250 million versus prior year. This updated guidance does not include any potential impacts from additional approvals of grandfathered applications." — Mike Marks, CFO

That is a $200M improvement to the full-year assumption, which in January was a decline of $250M to $450M. Total company guidance was left unchanged.

Assessment: Two of the three components of the January supplemental-decline assumption have now reversed. We wrote in January that the Texas Atlas pause was "about as recoverable as a policy setback gets," and it recovered inside one quarter. Georgia was not even on the January list. The company has now improved a guidance input by $200M and declined to raise the total, which means either management is holding the improvement as a buffer against the Q1 shortfall and residual exchange uncertainty, or something else in the plan deteriorated by a comparable amount. Management's framing supports the first reading, but did not exclude the second.

3. Exchange Attrition Lands at the Favorable End

The number the entire 2026 thesis turns on came in at approximately 15%, the low end of the modeled 15% to 20% decline, with the composition of where displaced patients went also tracking to or slightly better than plan.

"we thought that we would lose about 15% to 20% of volume, of people leaving the exchanges. And we -- we think we saw about a 15% decline in first quarter, so at the lower end of that." — Mike Marks, CFO

Management added that patients migrating to uninsured status were "just a little bit less than expected," with some converting to Medicare or Medicaid on age or changed life circumstances, while cautioning this was a slight improvement and not significant. The $600M to $900M full-year range was maintained.

Assessment: This is the datapoint that changes our rating. The bear case on HCA for three quarters has been that the exchange transition would prove worse than management's model. The first quarter of observed data says the opposite, on a measure constructed to include forward-looking grace-period attrition rather than only confirmed losses. Maintaining the range rather than narrowing it toward the low end is conservative given the evidence, and consistent with management's stated intent to reassess at mid-year.

4. Florida: The Unguided Item That Could Be Large

The Florida directed-payment program, pending at CMS since our initiation, remains unapproved and unguided. Management's language on its prospects strengthened materially this quarter.

"we do feel positive about the prospects of approval for the Florida program. And if approved, as I noted in my prepared comments, we believe it would result, not only in additional revenues, but those that may be significant." — Mike Marks, CFO

The program covers the period October 1, 2024 to September 30, 2025, which means an approval would carry a substantial retroactive component.

Assessment: Florida is HCA's largest state by facility concentration and the program covers a full twelve-month retroactive period. "May be significant" from a management team that has consistently refused to size unapproved programs is the strongest signal they have given on this. It sits entirely outside guidance. Given that Georgia and Texas Atlas both landed this quarter, the base rate for these approvals resolving favorably is improving. We do not model it, and we do weight it in the risk/reward.

5. Guidance Reaffirmed, With Real Slack Inside It

Management reaffirmed the January ranges without adjustment. Assembling the disclosed pieces, the reaffirmation is more conservative than it appears.

"we just felt like that it was appropriate not to change our total guidance range, even with the $200 million improvement in first quarter. A chunk of that really goes back to this temporal nature of the headwinds that we saw in first quarter being related to the seasonal volume impacts in the winter storm and the related cost impacts." — Mike Marks, CFO

The arithmetic, using management's own numbers: a $180M temporal headwind and a $120M supplemental variance net to roughly $60M of Q1 shortfall versus plan, against $200M of full-year supplemental improvement.

Assessment: Roughly $140M of net improvement is sitting inside a reaffirmed guide, before any contribution from Florida or further grandfathered approvals. Management explicitly said the remaining three quarters are "largely back on our original plan" for volume, exchanges, revenue and costs. A guide reaffirmed on those terms is a guide with a cushion, and this management team has now beaten its own range twice in the period we have covered.

6. North Carolina: The One Thing Genuinely Running Behind

Asked about hurricane-affected markets, the CEO gave the most candid negative of the call, and it is an operating problem rather than a policy one.

"North Carolina, here's the short story. Demand is above our expectation. It's costing us more to serve that demand because North -- Western North Carolina has a significant workforce deficit. We're having to bring in labor, nursing, nonnursing to support the demand... So we've seen more volume. It's cost us more to serve it. So we're a little bit behind our expectations in North Carolina on the bottom line." — Samuel Hazen, CEO

The CFO added that payer mix in North Carolina has also deteriorated as a consequence of the same workforce disruption in the local economy.

Assessment: This is the single item on the call where reality is worse than plan, and it is worth taking seriously precisely because it cuts against our first bull pillar. HCA's labor thesis is that staffing is no longer a capacity constraint; Western North Carolina is a live counterexample where premium labor is required to serve demand that exists. It is geographically contained and it is a reminder that the company-level contract labor ratio of roughly 4.2% averages across markets with very different conditions. Guidance already assumes no material year-over-year earnings improvement from hurricane markets, so this is absorbed rather than incremental.

7. The Medicaid Conversion Slowdown: A New Channel

Uninsured equivalent admissions rose approximately 16%, and only a little more than half of that traces to exchange migration. The balance is a slowdown in converting eligible patients onto Medicaid.

"we largely think about this as people, who, this year, are less willing to fill out Medicaid applications. And so we suspect that, that could be driven a bit by concerns around immigration and like. So that -- we're studying that. I'm not quite sure if that's the full reason why." — Mike Marks, CFO

Assessment: A genuinely new risk that did not exist in our prior framework. Patients who would previously have been converted to Medicaid coverage by HCA's Parallon financial counselors are now declining to apply, which moves them directly into uncompensated care. It is not inside the $600M to $900M exchange estimate because it is not an exchange phenomenon. Management is candid that it does not fully understand the cause. The offsetting consideration is that these are patients HCA was already treating, so the effect is on collection rather than on volume, and management said the quarter's uncompensated care was "largely in line with our expectations."

8. Denials and Underpayments Remain Elevated

The adversarial half of the payer relationship has not improved. Management described denial and underpayment activity as increasing broadly across payers and products, with Medicare Advantage singled out.

"we continue to experience increased activity levels with our payers on denials and underpayments pretty broadly across payers and across products. I mean I might continue to call out Medicare Advantage as being a specific driver within the product mix... our recoveries, our work around speed resolution, our work around appeals and getting these overturned or such that we were able to mitigate and not see a lot of year-over-year impact to earnings. But the denials and underpayments are still really high." — Mike Marks, CFO

Separately, the digital payer partnerships launched roughly 18 months ago were characterised as "good and early work products, but we have a long way to go."

Assessment: HCA is running to stand still here. Rising denial activity fully offset by rising recovery capability produces no year-over-year earnings impact, which is a win in the sense that it did not get worse and a cost in the sense that the recovery infrastructure is now a permanent expense line. The candour about the digital partnerships being early is a useful corrective to the more optimistic framing on the Q4 call.

9. Resiliency Holding, With Volume Leverage Lost

The $400M resiliency target embedded in guidance was reaffirmed, with the CEO acknowledging the quarter cost the company operating leverage that resiliency had to make up.

"When we get volume, whether it's respiratory volume or surgical volume, we get operating leverage. So we lost a little bit of that in the first quarter. But again, when you sort of normalized for that, as we exited the quarter, we felt good about the leverage we were seeing in the subsequent months." — Samuel Hazen, CEO

On the AI component specifically, the CEO named initiatives in deployment: ambient listening for physician documentation, a nurse handoff program, and case management tooling that contributed to the length-of-stay improvement.

Assessment: Still no cumulative figure against the original $600M to $800M target from 2023, which is now the third consecutive quarter that gap has gone unaddressed. But the 2026 target is inside guidance and management reaffirmed it after a quarter that made it harder to hit. Salaries and benefits improving 30bps and supplies 20bps in a negative-leverage quarter is supporting evidence that the program is doing something real.

10. Case Mix and Service Line Strength Beneath the Volume Miss

Excluding the respiratory distortion, the underlying case-mix picture improved. The CEO reported cardiac procedures growing significantly, trauma up 2.5%, rehabilitation services growing at a good pace, and receipts through HCA's patient logistics centers up 2.4%, a channel that skews to higher acuity as smaller community and rural hospitals transfer patients into HCA's tertiary and quaternary facilities.

"So when you look inside of our business, in the first quarter this year, we had really strong cardiac activity. So our cardiac procedures grew significantly. Trauma was up 2.5%, also driving acuity. We had rehab services grow at a very good pace." — Samuel Hazen, CEO

Assessment: The high-acuity franchise is intact and growing, which is the part of HCA's mix that carries the best economics and the widest competitive moat. Patient logistics receipts up 2.4% is the most interesting of these because it measures HCA's role as the regional referral destination, which is structural share gain rather than market growth. The volume miss was concentrated in the lowest-value category HCA serves.

11. Network Expansion Continues Through the Reset

Against the prior-year quarter, HCA expanded overall sites of care by more than 4%, increased hospital beds through capital spending by almost 1%, and added 4% to emergency room capacity. Capital expenditure of $1.119B in the quarter tracks against the raised $5.0B to $5.5B full-year range. Hospital count declined to 189 from 192 and freestanding surgery centers to 119 from 125, so the network is being reshaped as well as grown.

Assessment: Adding 4% to emergency room capacity in the same year management expects a 16% increase in uninsured admissions concentrated in emergency settings is a defensible operational decision and a margin risk. Emergency capacity is where the displaced exchange population arrives. HCA is building for the volume it expects; whether that volume pays is the open question. Meanwhile the divestiture of three hospitals and six surgery centers year over year is the quiet portfolio pruning that shows up as the gap between reported and same-facility growth.

Guidance & Outlook

Implied balance-of-year ramp. Q1 Adjusted EBITDA of $3.802B against a full-year range of $15.550B to $16.450B implies $11.748B to $12.648B across the remaining three quarters, a midpoint of $12.198B or $4.066B per quarter. That compares with $4.114B in Q4 2025 and $3.870B in Q3 2025, so the implied run rate is achievable but not trivially so, and it requires the volume recovery management described in February and March to persist. Management stated the last three quarters should run at 2% to 3% volume growth against prior year.

Street at. Consensus entering the print was approximately $7.15 on EPS and $19.11B on revenue, both of which the company essentially matched. The consequential gap was at the Adjusted EBITDA line, which management conceded fell short of a consensus it described as consistent with its own internal plan.

Guidance style. Unchanged and consistent: every identified headwind embedded at full weight, every unapproved upside excluded. The difference this quarter is that two of the excluded upsides converted (Georgia and Texas Atlas), which improved a guidance assumption by $200M without improving the guidance. That is now a documented pattern rather than an inference.

Analyst Q&A Highlights

How the Quarter Compared to Internal Expectations

The opening question asked simply how results measured against plan, and drew an unusually complete answer: a concession of shortfall, an anchoring of internal plan to consensus, and a full decomposition of the two offsetting drivers.

Q: "I appreciate the color on the respiratory, SDP and other components. Maybe you could just give us a rundown broadly of how your results compare to your internal expectations for the quarter?"
— Ben Hendrix, RBC Capital Markets

A: "our results were a bit short in terms of adjusted EBITDA to our internal expectations. Besides our internal expectations is being pretty consistent with the midpoint of our guidance in terms of growth, pretty consistent actually with consensus coming into the call. Really 2 main drivers in terms of the shortfall to internal expectations. The first one is this kind of shortfall in the seasonal volume uplift from respiratory in the winter storms, which was mostly offset by the net benefit from the supplemental payment programs."
— Mike Marks, CFO

Assessment: Management anchored internal expectations to both the guidance midpoint and consensus, then conceded a miss against both. That is a more useful disclosure than most companies provide and it removes any ambiguity about how to read an "in line" headline. It also establishes that the miss was roughly $60M net against plan, which is small relative to a $15.5B-plus annual base.

The Bridge Back to the Original Guide

The follow-up asked management to walk the components that get 2026 back to the January plan after a dynamic first quarter, and produced the $200M supplemental adjustment plus an explicit statement that the balance of the year is unchanged.

Q: "Can you just give us an update on the moving pieces that kind of get you back to the initial guide? Maybe walk us through the components of the EBITDA bridge as you see them today after such a dynamic first quarter?"
— Ben Hendrix, RBC Capital Markets

A: "We estimate that the Georgia approval and the reinstated Atlas program I previously discussed, will provide approximately $200 million of incremental net benefit for the full year that was not originally included in our guidance... And so at the end of the day, we just felt like that it was appropriate not to change our total guidance range, even with the $200 million improvement in first quarter."
— Mike Marks, CFO

Assessment: The clearest statement of embedded conservatism we have seen from this management team. A $200M improvement to a component assumption, disclosed, with the total range deliberately left alone. Management justified it by pointing to the temporal Q1 headwinds, but those headwinds were themselves largely offset within the quarter. The slack is real.

Netting the Quarter's Unusual Items

The most arithmetically precise question of the call attempted to net the moving parts into a single number and to establish what it means for the remaining three quarters. Management validated the construction.

Q: "Is the right way -- am I hearing you say, you basically had $180 million of negative impact from flu and weather in the first quarter? You picked up $120 million of benefit from DPPs in the first quarter that was not expected. So the net was a $60 million drag net of the unusual items or weather and flu... So you're ending up roughly $20 million if you maintain your guidance for Q2, Q3, Q4 better because of the incremental impact of DPP over the course of the year."
— A.J. Rice, UBS

A: "Yes. I think that's -- you're generally in the zone. I mean we view the $180 million headwind in the quarter as being temporal and not structural. So we don't think that will repeat... when we look at the rest of the year, and we think about the demand that we're seeing in the marketplace, we believe that we will be able to run between 2% to 3% volume growth in the next 3 quarters of prior year."
— Mike Marks, CFO

Assessment: "You're generally in the zone" confirms the net math and, with it, that the balance of the year carries a modest tailwind rather than a catch-up burden. The accompanying commitment to 2% to 3% volume growth over the next three quarters is the most specific forward operating statement of the call and the one against which the next two prints should be graded.

Exchange Patient Behavior and Uncompensated Care

A multi-part question on Florida timing, metal-tier migration and bad debt drew the fullest single answer of the call, covering the collectability question flagged as unquantified in our January note.

Q: "just on the Florida DPP, I do think there are some anxiety in the market because it's taking so long to approved. Do you have any color on maybe from a timing perspective when that could be approved? And then my real question is just on ACA, just with the increasingly uninsured and the bad debt, is that coming in line with your initial expectations?"
— Ann Hynes, Mizuho Securities

A: "as we came into our modeling, our models included some shift from silver, bronze. And what we're seeing is we study our patients so far is that there has been a bit of a shift from silver to bronze in the patient selection of metal tier. I wouldn't say, however, that, that shift is significant at this point, but there is some... I don't think that the -- the impact of the shift and the growth in the patient out dues is going to be overly material, given the relatively minor portion of our patient cash collections that relate to exchange patients."
— Mike Marks, CFO

Assessment: This closes the specific gap we identified in January, where management had flagged silver-to-bronze migration as a risk to the retained exchange book and declined to bound it. The answer is that it is happening, it is not significant so far, and it was inside the $600M to $900M estimate from the start. No timing was offered on Florida, which remains the honest position given it sits with CMS.

Grace-Period Accounting and Revenue Recognition

The most technically demanding question of the call probed whether the reported 15% exchange decline reflects confirmed attrition or includes an estimate for patients whose coverage status is not yet resolved.

Q: "I wanted to follow up on your comments around exchange patients sitting in the grace period in February and March that you might not get paid for. My understanding is that managed care will let you know who these patients are in real time and that their coverage is suspended. Is that right? And just to be clear, how do you treat these patients within the exchange volume decline of 15% in the first quarter?"
— Justin Lake, Wolfe Research

A: "we generally do not have reliable third-party visibility at the time of service whether a premium has been paid... For the first month of the grace period, the payer is required to cover the care. For the remaining 2 months, the payer is not required to cover any care episodes, unless the premium was called out by the enrollee... when we articulate that 15% drop in equivalent admissions, it contains both of those components and same thing with the impact on our revenue and earnings."
— Mike Marks, CFO

Assessment: The most important technical exchange of the quarter. The questioner's premise, that payers flag suspended coverage in real time, was corrected: HCA has no reliable standardized visibility at the point of service. That makes the 15% figure an estimate rather than a count, and management constructed it to include expected grace-period attrition rather than only confirmed losses. Forward-leaning, and therefore the conservative construction, which is why we weight it.

Whether January's Lost Volume Comes Back

A question separating recoverable from unrecoverable volume within the storm impact, which matters for whether the balance of the year carries a catch-up benefit.

Q: "On the impact from winter weather, should we expect any loss procedures in January to come back through the year? I think you said February, March volumes more in line or just wondering if you picked those January volumes up already."
— Ryan Langston, TD Cowen

A: "we do believe that from the winter storm, that we largely recovered the surgical component of that with the end of the quarter. What was not recovered and what drove the net volume impact here was really the emergency visits and the related emergency admissions, where there was really not a second chance to recapture that volume."
— Mike Marks, CFO

Assessment: The right distinction and an honest one. Deferred surgery reschedules; a missed emergency visit is gone. It also means investors should not model a Q2 catch-up benefit from January, which management reinforced by saying any residual recovery would be "sprinkled into our mix" indiscernibly. The $180M is a permanent loss to 2026, not a timing shift, which makes the reaffirmed guide slightly more impressive rather than less.

Whether Payer Behavior Is Deteriorating

A question on prior authorization and post-discharge denials, asked against the backdrop of an organized health-plan campaign on the topic, drew confirmation that denial pressure is rising and being fully offset.

Q: "the health plans are all on an organized campaign today on prior authorization. I just was wondering if you could talk about any of the -- any payer behavior changes, particularly post discharge denials? Anything new that you saw emerge within the quarter or year-to-date?"
— Whit Mayo, Leerink Partners

A: "even with the pretty significant increase in activity around denials and under payments that we are seeing, our recoveries, our work around speed resolution, our work around appeals and getting these overturned or such that we were able to mitigate and not see a lot of year-over-year impact to earnings. But the denials and underpayments are still really high."
— Mike Marks, CFO

Assessment: A neutral outcome achieved through rising effort. The earnings impact was neutralized, which is what matters this quarter, but the underlying trend is adverse and the mitigation is a permanent cost. Worth watching as a slow structural drag rather than an event risk, particularly with Medicare Advantage singled out as the driver in a payer category that grew 1.9% in the quarter.

What They're NOT Saying

1. What offsets the $200M supplemental improvement inside the reaffirmed guide. The Q1 net shortfall was roughly $60M and management called the headwinds temporal and the balance of the year "largely back on our original plan." That should leave roughly $140M of improvement flowing through. It did not, and no offsetting deterioration was named.
2. Any Florida timing. Management's confidence in approval strengthened notably but no expected timeline was given, and no size was attached beyond "may be significant" for a program covering a full retroactive year.
3. Cumulative progress against the $600M to $800M resiliency target. Third consecutive quarter unaddressed. The 2026 $400M figure is reaffirmed; the 2023 target remains unreconciled.
4. How large the Medicaid conversion slowdown is. Management identified it as driving a meaningful share of the 16% uninsured increase and attributed it speculatively to immigration concerns, while saying it is not fully understood. No dollar quantification, and it sits outside the exchange estimate.
5. The EHR migration. Not mentioned on this call at all, one quarter after being described as a foundational accelerating program. No cost, timeline or progress update.
6. Debt trajectory. Total debt rose to $48.023B from $46.492B at year-end, roughly $1.5B in a quarter with $1.571B of buyback and $1.119B of capex. Leverage was described as in the lower half of target, with no comment on the funding mix.
7. Professional fees specifically. Named as one of three drivers of the 90bp deterioration in other operating expenses, with no growth rate given, after two quarters of explicit quantification (11% in Q3 2025, high-single-digit guidance for 2026).
8. Q2 shape. Asked directly about the sequential move from Q1 to Q2 Adjusted EBITDA, management declined beyond pointing to normal seasonality.

Market Reaction

• Pre-print setup: HCA closed at $474.03 on April 23, up 1.5% year to date against the S&P 500 at +3.8%, up 38.8% over trailing twelve months and down 2.1% over the trailing thirty days. The 52-week closing range entering the print was $324.62 to $545.13, so the stock came in roughly 13% below its high.
• Reaction session (April 24, before-open reporter): Opened at $430.00, a 9.3% gap down, traded $422.19 to $451.57 (-10.9% to -4.7% versus the prior close), and closed at $432.46, down 8.8% or $41.57. The S&P 500 rose 0.8% the same session.
• Volume: 3.3 million shares against a 30-day average of 1.0 million, or 3.4x normal.

An 8.8% decline on an in-line revenue and EPS print, with guidance reaffirmed, is a reaction to composition rather than to the headline. Three things drove it. Same-facility equivalent admissions of 1.3% printed below the 2% to 3% assumption that underpins the entire full-year guide. Adjusted EBITDA missed both internal plan and consensus, which management confirmed on the call. And the quality of the earnings was visibly poor, with income before taxes down 1.7% and 93% of EPS growth coming from share count.

The intraday path suggests the selling was front-loaded and largely done at the open. The stock gapped 9.3% lower on the press release, made its low at $422.19, and then recovered to close at $432.46, above the open. The call, which contained the favorable exchange data and the improved supplemental-payment assumption, coincided with the recovery off the low. The market punished the print and then partially re-rated on the detail, which is close to the opposite of the Q3 2025 pattern where a strong headline faded as the composition emerged.

Volume at 3.4x normal on a session where the S&P rose 0.8% indicates genuine repositioning rather than drift. Investors who owned HCA for the 2% to 3% volume algorithm saw that algorithm break in the first quarter of the year it was supposed to be defended, and did not stay to litigate why.

Street Perspective

Debate: Is the Volume Miss Temporal or the Start of Structural Erosion?

Bull view: A 42% decline in respiratory admissions is epidemiology, not demand. The impact was quantified at 70bps on admissions and 140bps on ER visits, the storm added 30bps and 50bps, and management said February and March rebounded with cost trends back on plan by March. Add back the drags and same-facility admissions growth is inside the range.

Bear view: Commercial ex-exchanges grew 0.6%, Medicare 1.9% and Medicaid 0.3%, all decelerating. Attributing every category's weakness to flu and one storm is convenient. If the underlying growth algorithm is closer to 1% than 2.5%, the entire guide is unreachable regardless of the exchange outcome.

Our take: The bull case has the better evidence, but the bear case identifies the right test. Management said the respiratory and storm effects were "consistent across all payer categories," which is a testable claim: if Q2 payer-category growth normalizes toward 2% to 3% without a seasonal tailwind, the temporal explanation holds. If commercial ex-exchanges is still near 1% in July, the algorithm has changed. We lean temporal because the drags were specifically quantified and because occupancy at 75.5% indicates the demand was there.

Debate: Does the Exchange Data Point De-Risk the Year?

Bull view: Attrition at approximately 15% against a 15% to 20% model, employer-coverage migration inside plan, uninsured migration slightly better, metal-tier shift present but not significant, and the 15% figure constructed to include forward-looking grace-period attrition rather than only confirmed losses. This is the central bear risk of the last three quarters resolving at the favorable end on first observation.

Bear view: One quarter of a multi-quarter transition, built on estimates for patients whose coverage status will not resolve until Q2. Management said the environment "has not fully settled" and declined to narrow the range. A new leak appeared that nobody modelled, the Medicaid conversion slowdown, which pushed uninsured admissions up 16%.

Our take: The bulls have the stronger read and the bears have identified the right caveat. What tips it is the construction of the 15%: including estimated grace-period attrition makes it forward-leaning rather than a lagging count, which is the conservative choice and the harder one to fault. The Medicaid conversion slowdown is a genuine new issue and belongs on the thesis as a separate risk, but it affects collection on patients already being treated rather than the exchange model itself.

Debate: Is 14.3x Too Cheap for a Flat-Earnings Year?

Bull view: The multiple has compressed from 16.7x to 14.3x in three months on a guide that was reaffirmed with roughly $140M of net improvement embedded inside it, plus two excluded upside channels of which Florida is described by management as potentially significant. Q1's $180M drag is confirmed non-recurring. The buyback has $9.179B of authorization remaining against a market value near $98B.

Bear view: 14.3x on an EPS number where 93% of the growth is share count is not obviously cheap; on flat net income the multiple on actual earnings power has not moved. Income before taxes declined, other operating expenses deteriorated 90bps, North Carolina is behind plan, and 2027 laps into OBBBA Medicaid provisions from 2028.

Our take: This is where we change our view. The bear points are all accurate and were already known when we rated the stock Hold at $505.84 in January. What has changed is the price, down 14.5%, and the resolution of the single largest uncertainty in the favorable direction. Buying a business at 14.3x whose main bear risk has just been measured and found smaller than feared, with a guide carrying documented slack and a large unguided catalyst pending at CMS, is a different proposition than paying 16.7x for the same business on an unobserved model.

Model Update Needed

Valuation framework. At the April 24 close of $432.46, HCA trades at 14.3x the midpoint of guided 2026 diluted EPS of $29.10 to $31.50, down from 16.7x when we last wrote. On our own estimate of $30.50 to $31.00, the multiple is roughly 14.1x. Retaining the 15.5x to 17.5x range we applied in January to a midpoint estimate of $30.75 yields a fair value band of roughly $475 to $540, midpoint about $505, implying roughly +17% from the current price. We hold the multiple range constant deliberately: nothing about the business quality changed this quarter, only the price and the resolution of an uncertainty. The Florida program and any further grandfathered approvals are excluded from both the estimate and the band.

Thesis Scorecard Post-Earnings

Overall: Thesis improved where it mattered most. The two policy-driven bear points that dominated this coverage since initiation both moved to Contained: exchange attrition landed at the favorable end of the model on first observation, and the supplemental payment channel reversed $200M in HCA's favor. Against that, the operating pillars softened to Neutral on a quarter distorted by weather and virology, and Bear #4 materialized exactly as forecast. A fifth bear point is added for the Medicaid conversion slowdown, which is a genuinely new channel.

Action: Upgrade to Outperform. In January we wrote that we would revisit constructively "on any pullback toward the mid $400s, or on Q1 evidence that exchange attrition is tracking at the low end of the 15% to 20% assumption." Both triggers fired in the same session. We are not upgrading because the quarter was good; it was not. We are upgrading because a 14.5% de-rating has been applied to a business whose central risk was just measured and found smaller than feared, whose reaffirmed guide carries roughly $140M of documented slack, and which has a potentially significant retroactive Florida approval sitting entirely outside guidance. Fair value band $475 to $540, midpoint approximately $505. The Q2 print in late July is the checkpoint: it should confirm 2% to 3% volume growth, resolve the grace-period estimates, and may carry a Florida decision.